Ключевые слова:
гормон роста, инсулиноподобный фактора роста–1, рак молочной железы, генетика.Библиографические ссылки
Limonta P, Moretti RM, Marzagalli M, Fontana F, Raimondi M, Marelli MM. Role of endoplasmic reticulum stress in the anticancer activity of natural compounds. Int J Mol Sci. 2019;20(4):961. https:// doi.org/10.3390/ijms20040961
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. https:// doi.org/ 10.3322/caac.21492
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019; 144(8):1941–53. https://doi.org/10.1002/ ijc.31937
Costa–Silva DR, Barros–Oliveira MC, Borges RS, CamposVerdes LM, da Silva–Sampaio JP, Escorcio–Dourado CS, et al. Insulin–like growth factor 1 gene polymorphism in women with breast cancer. Med Oncol. 2017; 34(4):59. https://doi. org/10.1007 /s12032–017–0915–4
Campos–Verdes LM, da Silva–Sampaio JP, Costa–Silva DR, de Oliveira VA, Conde Junior AM, Silva VC, et al. Genetic polymorphism of calcium–sensing receptor in women with breast cancer. Med Oncol. 2018; 35(3):23. https://doi.org/10.1007/s12 032–018–1089–4
Abu–Helalah M, Azab B, Mubaidin R, Ali D, Jafar H, Alshraideh H, et al. BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan. Sci Rep. 2020; 10(1):17573. https://doi.org/ 10.1038/s41598–020–74250–2
Raval A, Trivedi S. Breast cancer: role of IGF–1 and IGFBP–3 expression in prognostication. Indian J Exp Biol. 2016;54(10):619– 29. PMID: 300 84561
Cevenini A, Orrù S, Mancini A, Alfieri A, Buono P, Imperlini E. Molecular signatures of the insulin–like growth factor 1–mediated epithelial–mesenchymal transition in breast, lung and gastric cancers. Int J Mol Sci. 2018;19(8):2411. https:// doi.org/ 10.3390/ijms19082411
Ipsa E, Cruzat VF, Kagize JN, Yovich JL, Keane KN. Growth hormone and insulin–like growth factor action in reproductive tissues. Front Endocrinol (Lausanne). 2019; 10:777. https:// doi.org/ 10.3389/fendo.2019.00777
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ. 2009; 339: b2535. https://doi.org/ 10.1136/bmj.b2535
Chong KYM, Subramanian A, Mokbel K, Sharma AK. The prognostic significance of the insulin–like growth factor–1 ligand and receptor expression in breast cancer tissue. J Surg Oncol. 2011; 104(3):228–35. https://doi.org/10.1002/jso.21916
Christodoulou C, Oikonomopoulos G, Koliou GA, Kostopoulos I, Kotoula V, Bobos M, et al. Evaluation of the insulin–like growth factor receptor pathway in patients with advanced breast cancer treated with trastuzumab. Cancer Genomics Proteomics. 2018; 15(6):461–71. https://doi.org/10.21 873/cgp.20105
Mu L, Tuck D, Katsaros D, Lu L, Schulz V, Perincheri S, et al. Favorable outcome associated with an IGF–1 ligand signature in breast cancer. Breast Cancer Res Treat. 2012; 133(1): 321–31. https://doi.org/10.1007/s10549–012–1952–5
De Santi M, Annibalini G, Barbieri E, Villarini A, Vallorani L, Contarelli S, et al. Human IGF1 pro–forms induce breast cancer cell proliferation via the IGF1 receptor. Cell Oncol (Dordr). 2016; 39(2): 149–59. https://doi.org/10.1007/s13402–015– 02 63–3.
Ruan W, Kleinberg DL. Insulin–like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology. 1999;140:5075–81.
Deeks S, Richards J, Nandi S. Maintenance of normal rat mammary epithelial cells by insulin and insulin–like growth factor 1. Exp Cell Res. 1988; 174:448–60.
Sarfstein R, Pasmanik–Chor M, Yeheskel A, Edry L, Shomron N, Warman N, et al. Insulin–like Growth Factor–I Receptor (IGF–IR) translocates to nucleus and autoregulates IGF–IR gene expression in breast cancer cells. J Biol Chem. 2012; 287:2766–76.
Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERα through a S6K1–dependent mechanism in breast cancer cells. Mol Endocrinol. 2011; 25:516–28.
Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, et al. Plasma insulin–like growth factor–1 (IGF–1) concentrations in human breast cancer. Eur J Cancer Oxf Engl 2010. 1993; 29A: 492–7.
Kang HJ, Yi YW, Kim HJ, Hong YB, Seong YS, Bae I. BRCA1 negatively regulates IGF–1 expression through an estrogen–responsive element–like site. Cell Death Dis. 2012; 3:e336.
Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 2005; 16: 421–39.
Philippou A, Maridaki M, Pneumaticos S, Koutsilieris M. The complexity of the IGF1 gene splicing, post–translational modification and bioactivity. Mol Med Camb Mass. 2014; 20:202–14.
Macias H, Hinck L. Mammary gland development. Wiley Interdiscip Rev Dev Biol. 2012; 1: 533 –57.
Yu H, Rohan T. Role of the insulin–like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92:1472–89.
Diorio C, Pollak M, Byrne C, Mâsse B, Hébert–Croteau N, Yaffe M, et al. Insulin–like growth factor–I, IGF–binding protein–3, and mammographic breast density. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2005; 14:1065–73.
Gennigens C, Menetrier–Caux C, Droz JP. Insulin–Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol. 2006; 58:124–45.
Philippou A, Halapas A, Maridaki M, Koutsilieris M. Type I insulin–like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact. 2007; 7:208–18.
Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado–Heinsohn E, Osborne CK, et al. Enhancement of insulin–like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate–1 expression in vitro and in vivo. Mol Endocrinol Baltim Md. 1999; 13:787–96.
LeRoith D, Roberts CT. The insulin–like growth factor system and cancer. Cancer Lett. 2003; 195:127–37.
Al–Ajmi K, Ganguly SS, Al–Ajmi A, Mandhari ZA, Al–Moundhri MS. Insulin–like growth factor 1 gene polymorphism and breast cancer risk among Arab Omani women: a case–control study. Breast Cancer (Auckl). 2012; 6:103–12.
Sarkissyan M, Mishra DK, Wu Y, Shang X, Sarkissyan S, Vadgama JV. IGF gene polymorphisms and breast cancer in African–American and Hispanic women. Int J Oncol. 2011; 38:1663–73.
Huang Q, Wang C, Qiu L–J, Shao F, Yu J–H. The association between IGF1 CA repeat polymorphisms and breast cancer risk: a meta–analysis. Breast Cancer Res Treat. 2011; 129:191–4.
He B, Xu Y, Pan Y, Li R, Gao T, Song G, et al. Differential effects of insulin–like growth factor–1 CA repeat polymorphism on breast cancer risk along with race: a meta–analysis. Gene. 2013; 525:92–8.
Quan H, Tang H, Fang L, Bi J, Liu Y, Li H. IGF1 (CA)19 and IGFBP–3–202A/C gene polymorphism and cancer risk: a meta–analysis. Cell Biochem Biophys. 2014; 69:169–78.
Javadi M, Hematti S, Tavassoli M. Polymorphic CA repeat length in insulin–like growth factor 1 and risk of breast cancer in Iranian women. Med Oncol. 2012; 29:516–20.
Biong M, Gram IT, Brill I, Johansen F, Solvang HK, Alnaes GIG, et al. Genotypes and haplotypes in the insulin–like growth factors, their receptors and binding proteins in relation to plasma metabolic levels and mammographic density. BMC Med Genomics. 2010; 3:9.
Henningson M, Hietala M, Törngren T, Olsson H, Jernström H. IGF1 htSNPs in relation to IGF–1 levels in young women from high–risk breast cancer families: implications for early–onset breast cancer. Fam Cancer. 2011; 10:173–85.
Qian B, Zheng H, Yu H, Chen K. Genotypes and phenotypes of IGF–I and IGFBP–3 in breast tumors among Chinese women. Breast Cancer Res Treat. 2011; 130:217–26.
Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, et al. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin–like growth factor–I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet. 2010; 19:3873–84.
Gu F, Schumacher FR, Canzian F, Allen NE, Albanes D, Berg CD, et al. Eighteen insulin–like growth factor pathway genes, circulating levels of IGF–I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010; 19:2877–87.
Yaren A, Turgut S, Ayada C, Akcilar R, Degirmencioglu S, Gokoz Dogu G. Insulin–like growth factor I (Igf–1) gene polymorphism in patients with nonmetastatic breast cancer. Gene. 2012;503:244–7.
Muendlein A, Lang AH, Geller–Rhomberg S, Winder T, Gasser K, Drexel H, et al. Association of a common genetic variant of the IGF–1 gene with event–free survival in patients with HER2–positive breast cancer. J Cancer Res Clin Oncol. 2013; 139: 491–8.
Lindström S, Thompson DJ, Paterson AD, Li J, Gierach GL, Scott C, et al. Genome–wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun. 2014; 5:5303.
Chong KYM, Subramanian A, Mokbel K, Sharma AK. The prognostic significance of the insulin–like growth factor–1 ligand and receptor expression in breast cancer tissue. J Surg Oncol. 2011; 104: 228–35.
Mu L, Tuck D, Katsaros D, Lu L, Schulz V, Perincheri S, et al. Favorable outcome associated with an IGF–1 ligand signature in breast cancer. Breast Cancer Res Treat. 2012; 133:321–31.
Llanos AA, Brasky TM, Dumitrescu RG, Marian C, Makambi KH, Kallakury BVS, et al. Plasma IGF–1 and IGFBP–3 may be imprecise surrogates for breast concentrations: an analysis of healthy women. Breast Cancer Res Treat. 2013; 138:571–9.
Richards RG, Klotz DM, Walker MP, Diaugustine RP. Mammary gland branching morphogenesis is diminished in mice with a deficiency of insulin–like growth factor–I (IGF–I), but not in mice with a liver–specific deletion of IGF–I. Endocrinology. 2004; 145: 3106–10.
Davison Z, de Blacquière GE, Westley BR, May FE. Insulin–like growth factor–dependent proliferation and survival of triple–negative breast cancer cells: implications for therapy. Neoplasia N Y NY. 2011; 13:504.
D’Esposito V, Passaretti F, Hammarstedt A, Liguoro D, Terracciano D, Molea G, et al. Adipocyte–released insulin–like growth factor–1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia. 2012; 55: 2811–22.
Pollak M. Insulin and insulin–like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8:915–28.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406:747–52.
Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer. 2001; 8:197–209.
Rinaldi S, Biessy C, Hernandez M, Lesueur F, dos Santos Silva I, Rice MS, et al. Circulating concentrations of insulin–like growth factor–I, insulin–like growth factor–binding protein–3, genetic polymorphisms and mammographic density in premenopausal Mexican women: Results from the ESMaestras cohort: IGF–I, IGFBP–3 and mammographic density in women. Int J Cancer. 2014; 134:1436–44.
D’Esposito V, Passaretti F, Hammarstedt A, Liguoro D, Terracciano D, Molea G, et al. Adipocyte–released insulin–like growth factor–1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia. 2012; 55:2811–22.
Rajski M, Zanetti–Dällenbach R, Vogel B, Herrmann R, Rochlitz C, Buess M. IGF–I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med. 2010; 8:1.
Gilam A, Edry L, Mamluk–Morag E, Bar–Ilan D, Avivi C, Golan D, et al. Involvement of IGF–1R regulation by miR–515–5p modifies breast cancer risk among BRCA1 carriers. Breast Cancer Res Treat. 2013; 138: 753–60.
Winder T, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, et al. Insulin–like growth factor receptor polymorphism defines clinical outcome in estrogen receptor–positive breast cancer patients treated with tamoxifen. Pharmacogenomics J. 2014; 14: 28–34.
Kang H–S, Ahn SH, Mishra SK, Hong K–M, Lee ES, Shin KH, et al. Association of polymorphisms and haplotypes in the insulin–like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women. PLoS ONE. 2014; 9:e84532
Hua H, Kong Q, Yin J, Zhang J, Jiang Y. Insulin–like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. J Hematol Oncol. 2020; 13(1):64. https:// doi.org/10.1186/s13045–020–00904–3.
Laron, Z.; Werner, H. Laron syndrome–A historical perspective. Rev. Endocr. Metab. Disord. 2020, 22, 31–41. [CrossRef].
Fuentes, N.; Silveyra, P. Estrogen receptor signaling mechanisms. Adv. Protein Chem. Struct. Biol. 2019, 116, 135–170. [CrossRef] [PubMed].
Murphy, N.; Knuppel, A.; Papadimitriou, N.; Martin, R.M.; Tsilidis, K.K.; Smith–Byrne, K.; Fensom, G.; Perez–Cornago, A.; Travis, R.C.; Key, T.J.; et al. Insulin–like growth factor–1, insulin–like growth factor–binding protein–3, and breast cancer risk: Observational and Mendelian randomization analyses with approximately 430,000 women. Ann. Oncol. 2020, 31, 641–649. [CrossRef] [PubMed]
Qian, F.; Huo, D. Circulating Insulin–Like Growth Factor–1 and Risk of Total and 19 Site–Specific Cancers: Cohort Study Analyses from the UK Biobank. Cancer Epidemiol. Biomark. Prev. 2020, 29, 2332–2342. [CrossRef].
Tian J, Berton TR, Shirley SH, Lambertz I, Gimenez–Conti IB, DiGiovanni J, et al. Developmental stage determines estrogen receptor alpha expression and non–genomic mechanisms that control IGF–1 signaling and mammary proliferation in mice. J Clin Invest. 2021; 122:192–204